Olive Leaf Extracts in the Control of Diabet

PHASE2/PHASE3RecruitingINTERVENTIONAL
Enrollment

500

Participants

Timeline

Start Date

January 1, 2023

Primary Completion Date

September 15, 2025

Study Completion Date

December 15, 2025

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

Atherolive

The patient will be assigned using a computer-generated randomization list (1: 1 allocation). The investigator who has the randomization code is not involved in other study procedures and does not interact with participants. The study drug (atherol) will be prescribed at a dose of 400 mg, once a day for 3 months.

DRUG

Placebo Atherolive

The patient will be assigned using a computer-generated randomization list (1: 1 allocation). The investigator who has the randomization code is not involved in other study procedures and does not interact with participants. The placebo will be prescribed at a dose of 400 mg once a day for 3 months.

Trial Locations (1)

5000

RECRUITING

Semir Nouira, Monastir

All Listed Sponsors
lead

University of Monastir

OTHER